CoChat

Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity

Kotanides, Helen, Li, Yiwen, Malabunga, Maria, Carpenito, Carmine, Eastman, Scott W., Shen, Yang, Wang, George, Inigo, Ivan, Surguladze, David, Pennello, Anthony L., Persaud, Krishnadatt, Hindi, Sagit, Topper, Michael, Chen, Xinlei, Zhang, Yiwei, Bulaon, Danielle K., Bailey, Tim, Lao, Yanbin, Han, Bing, Torgerson, Stacy, Chin, Darin, Sonyi, Andreas, Haidar, Jaafar N., Novosiadly, Ruslan D., Moxham, Christopher M., Plowman, Gregory D., Ludwig, Dale L., Kalos, Michael · 2020 · Cancer Immunology Research
Cited by 65

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

The programmed cell death protein 1 receptor (PD-1) and programmed death ligand 1 (PD-L1) coinhibitory pathway suppresses T-cell–mediated immunity. We hypothesized that cotargeting of PD-1 and PD-L1 with a bispecific antibody molecule could provide an alternative therapeutic approach, with enhanced antitumor activity, compared with monospecific PD-1 and PD-L1 antibodies. Here, we describe LY3434172, a bispecific IgG1 mAb with ablated Fc immune effector function that targets both human PD-1 and PD-L1. LY3434172 fully inhibited the major inhibitory receptor–ligand interactions in the PD-1 pathway. LY3434172 enhanced functional activation of T cells in vitro compared with the parent anti–PD-1 and anti–PD-L1 antibody combination or respective monotherapies. In mouse tumor models reconstituted with human immune cells, LY3434172 therapy induced dramatic and potent antitumor activity compared with each parent antibody or their combination. Collectively, these results demonstrated the enhanced immunomodulatory (immune blockade) properties of LY3434172, which improved antitumor immune response in preclinical studies, thus supporting its evaluation as a novel bispecific cancer immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-20-0304

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 65

Metadata

Authors
Kotanides, H., Li, Y., Malabunga, M., Carpenito, C., Eastman, S. W., Shen, Y., Wang, G., Inigo, I., Surguladze, D., Pennello, A. L., Persaud, K., Hindi, S., Topper, M., Chen, X., Zhang, Y., Bulaon, D. K., Bailey, T., Lao, Y., Han, B., Torgerson, S., Chin, D., Sonyi, A., Haidar, J. N., Novosiadly, R. D., Moxham, C. M., Plowman, G. D., Ludwig, D. L., & Kalos, M.
Venue
Cancer Immunology Research
Published
2020-10-01
Volume
8
Issue
10
Pages
1300-1310
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W3043895034
Cited by
65
References
17
FWCI
2.57
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity. https://app.cochat.ai/papers/10.1158/2326-6066.cir-20-0304
The paper
Kotanides, H., Li, Y., Malabunga, M., Carpenito, C., Eastman, S. W., Shen, Y., Wang, G., Inigo, I., Surguladze, D., Pennello, A. L., Persaud, K., Hindi, S., Topper, M., Chen, X., Zhang, Y., Bulaon, D. K., Bailey, T., Lao, Y., Han, B., . . . Kalos, M. (2020). Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-20-0304

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.